ATE342358T1 - Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen - Google Patents

Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen

Info

Publication number
ATE342358T1
ATE342358T1 AT98915305T AT98915305T ATE342358T1 AT E342358 T1 ATE342358 T1 AT E342358T1 AT 98915305 T AT98915305 T AT 98915305T AT 98915305 T AT98915305 T AT 98915305T AT E342358 T1 ATE342358 T1 AT E342358T1
Authority
AT
Austria
Prior art keywords
delta3
therapeutic
composition
differentiation
diagnostic uses
Prior art date
Application number
AT98915305T
Other languages
English (en)
Inventor
Sean A Mccarthy
David P Gearing
Original Assignee
Millennium Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE342358(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/872,855 external-priority patent/US6121045A/en
Application filed by Millennium Biotherapeutics Inc filed Critical Millennium Biotherapeutics Inc
Application granted granted Critical
Publication of ATE342358T1 publication Critical patent/ATE342358T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98915305T 1997-04-04 1998-04-06 Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen ATE342358T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83263397A 1997-04-04 1997-04-04
US08/872,855 US6121045A (en) 1997-04-04 1997-06-11 Human Delta3 nucleic acid molecules

Publications (1)

Publication Number Publication Date
ATE342358T1 true ATE342358T1 (de) 2006-11-15

Family

ID=27125549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915305T ATE342358T1 (de) 1997-04-04 1998-04-06 Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen

Country Status (8)

Country Link
EP (1) EP0972041B2 (de)
JP (1) JP2001521382A (de)
AT (1) ATE342358T1 (de)
AU (1) AU6952498A (de)
CA (1) CA2285020A1 (de)
DE (1) DE69836131T3 (de)
ES (1) ES2275304T3 (de)
WO (1) WO1998045434A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723939B2 (en) 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
CA2288218C (en) * 1997-05-14 2013-03-12 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation-inhibitor
AU4870599A (en) * 1998-07-27 2000-02-21 Amgen, Inc. Delta-related polypeptides
JP2003507029A (ja) * 1999-08-19 2003-02-25 カイロン コーポレイション Ｎｏｔｃｈレセプターリガンドおよびその使用
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
WO2003018799A2 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
DK2500360T3 (en) 2005-10-31 2015-10-26 Oncomed Pharm Inc Compositions and methods for the diagnosis and treatment of cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
BRPI0710413A2 (pt) 2006-06-06 2011-08-23 Genentech Inc anticorpos anti-dll4, isolados, polinucleotìdeo, vetor, célular hospedeira, método para produção de um anticorpo anti-dll4, método para produção de um imunoconjugado anti-dll4, método para a detecção de dll4, metodo para diagnosticar um distúrbio, composições, método para tratar um tumor, cáncer e/ou disturbio da proliferação celular e método para melhorar a eficácia de um agente anti-angiogênico
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2106439B1 (de) 2007-01-24 2014-11-12 The Regents of the University of Michigan Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2356146A1 (de) 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4-antikörper und anwendungen davon
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US9127071B2 (en) 2010-01-29 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Anti-DLL3 antibody
EP2552953B1 (de) 2010-04-01 2017-05-17 OncoMed Pharmaceuticals, Inc. Frizzled-bindende stoffe und ihre verwendungen
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU723939B2 (en) 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
EP0861894B1 (de) * 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt

Also Published As

Publication number Publication date
EP0972041B1 (de) 2006-10-11
EP0972041B2 (de) 2017-01-18
AU6952498A (en) 1998-10-30
DE69836131T2 (de) 2007-08-30
DE69836131D1 (de) 2006-11-23
EP0972041A1 (de) 2000-01-19
ES2275304T3 (es) 2007-06-01
CA2285020A1 (en) 1998-10-15
DE69836131T3 (de) 2017-06-14
WO1998045434A1 (en) 1998-10-15
JP2001521382A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
ATE342358T1 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
IL115517A0 (en) Biologically active proteins
Lappi et al. Biological and chemical characterization of basic FGF-saporin mitotoxin
DE69937752D1 (de) Modifizierte peptide als therapeutische mittel
AU1922101A (en) Human fgf-21 gene and gene expression products
DE69630710D1 (de) Humaner tumornekrosefaktor delta und epsilon
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
ATE417057T1 (de) Mutierte formen des fas liganden und deren verwendung
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
EP1978362A3 (de) Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
BR9607628A (pt) Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero
MXPA02008239A (es) Gen humano de la esquizofrenia.
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
WO1999033870A3 (en) Human regulatory proteins
DE69433902D1 (de) Neuartige tyrosinkinase
DE69839733D1 (de) Mit syndekan interagierende proteine und deren verwendung
WO1999046381A3 (en) Human fgf gene and gene expression products
MX9801603A (es) Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties